中国药物经济学2025，Vol.20Issue(8)：19-22,42,5.DOI:10.12010/j.issn.1673-5846.2025.08.003
夏枯草制剂联合左甲状腺素钠片治疗甲状腺结节的药物经济学评价
Pharmacoeconomic Evaluation of Prunella Vulgaris Preparations combined with Levothyroxine Sodium Tablets in the Treatment of Thyroid Nodules
蔡佳芮 1盖巧玥 1江庆玲 1刘振谧1
作者信息
- 1. 四川大学华西第四医院,成都 610041
- 折叠
摘要
Abstract
Objective To evaluate the economic viability of Prunella vulgaris preparations combined with levothyroxine sodium tablets in the treatment of thyroid nodules.Methods Based on the meta-analysis results of this study,from the perspective of the health system,a decision tree model was used to conduct a cost-effectiveness analysis of the treatment of thyroid nodules with Prunella vulgaris preparations combined with levothyroxine sodium tablets and levothyroxine sodium tablets,and a sensitivity analysis was also carried out.Results Basic analysis shows that the cost of Prunella vulgaris preparations combined with sodium levothyroxine tablets is higher than that of sodium levothyroxine tablets alone,and the clinical effective rate is higher than that of the single group.After calculation,the incremental cost-effectiveness ratio(ICER)of the treatment regimens in the two groups ranged from 7.10 to 19.51.Taking the per capita disposable income of 36 883 yuan in 2022 as the reference threshold for the basic analysis,the ICER was significantly lower than the per capita disposable income.The treatment plan combining Prunella vulgaris preparations with lethyroxine sodium tablets was more economical.The results of the single-factor sensitivity analysis indicated that the basic analysis results were relatively robust.Conclusion The combination of Prunella vulgaris preparations and levothyroxine sodium tablets in the treatment of thyroid nodules has a good clinical efficacy and is economically efficient.关键词
药物经济学/甲状腺结节/夏枯草/左甲状腺素钠片/成本-效果分析Key words
Pharmacoeconomics/Thyroid nodules/Lithospermum erythrorhizon/Levothyroxine sodium tablets/Cost-effectiveness analysis分类
医药卫生引用本文复制引用
蔡佳芮,盖巧玥,江庆玲,刘振谧..夏枯草制剂联合左甲状腺素钠片治疗甲状腺结节的药物经济学评价[J].中国药物经济学,2025,20(8):19-22,42,5.
